AnaptysBio’s Imsidolimab Meets Yet Another Failure

 
• By Alaric DeArment
  
AnaptysBio is shifting its strategy after another trial of imsidolimab failed • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D